Koo thanks for posting this epigenetic summary, it is a good reminder that there are others out there. In particular the Constellation acquisition by MorphoSys is a reminder that in the right hands there is a lot of value in epigenetics. It is also interesting to remember that Don's "friend" Pablo at Royalty Pharma provided MorphoSys the funding to allow that deal to happen and a small part of Royalty Pharma's compensation is a royalty on Pelabresib, the BET inhibitor MorphoSys (Constellation) is developing.